-
公开(公告)号:US20060026702A1
公开(公告)日:2006-02-02
申请号:US10902137
申请日:2004-07-30
IPC分类号: G01N33/53 , G01N33/567 , A01K67/027
CPC分类号: A01K67/0275 , A01K2217/05 , G01N33/566 , G01N2333/726 , G01N2500/10
摘要: The present invention relates to compounds that alter GPCR internalization and new methods for their identification. Compounds of this invention include modified phosphoinositide 3-kinase (PI3K), modified HEAT domain, modified β-adrenergic receptor kinase 1 (βARK1), as well as other peptides or small molecules that alter GPCR internalization. The present invention also includes the use of such compounds to treat GPCR-related diseases, such as cardiovascular disease, heart failure, asthma, nephrogenic diabetes insipidus, or hypertension.
-
公开(公告)号:US06610532B2
公开(公告)日:2003-08-26
申请号:US09121814
申请日:1998-07-24
IPC分类号: A61K4800
CPC分类号: C07K14/4722 , A01K67/0278 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A01K2267/0375 , A61K38/00 , A61K48/00 , C12N15/8509 , C12N2830/008
摘要: The present invention relates, in general, to myocardial hypertrophy and, in particular, to agents that inhibit cardiac Gq-coupled receptor signaling and to methods of inhibiting myocardial hypertrophy using same.
-